Introduction
RNA interference (RNAi) is a post-transcriptional genesilencing mechanism in which small interfering 21-to 23-mer double-stranded RNA (small interfering RNA (siRNA)) mediates sequence-specific degradation of mRNA. 1 The discovery that exogenously delivered siRNA can trigger RNAi in mammalian cells raises the possibility of harnessing RNAi technology as a therapeutic tool against pathogenic viruses.
2,3 Several groups including our own have shown that siRNAs targeted to human immunodeficiency virus-1 (HIV-1) genome or its receptor CCR5 specifically suppress HIV-1 replication in T cells and macrophages. [4] [5] [6] In these studies, a general adopted approach is to stably express in the target cell a short hairpin RNA (shRNA) that can be processed into siRNA by endogenous RNase III-like enzyme Dicer in the cytoplasm. [7] [8] [9] [10] [11] Most studies used polymerase (pol) III promoters to control the expression of the shRNA gene. 5, [12] [13] [14] [15] [16] [17] The transcription initiation site of a pol III promoter is well defined and transcription termination occurs at a stretch of four consecutive T residues in the DNA template. 18 Well-defined ends of a shRNA are critical for Dicer-mediated processing to generate the mature siRNA. In addition, pol III promoters function ubiquitously and direct high-level gene expression. However, An et al. 19 recently showed that high-level expression of shRNAs from a potent pol III promoter led to a decline of the transduced human lymphocytes in culture. Grimm et al. 20 showed that in vivo shRNA expression from a strong pol III promoter-induced tissue damage and lethality in adult mice. They linked the observed toxicity to in vivo shRNA overexpression that competed with endogenous microRNA (miRNA) for shRNA/miRNA exporting factors such as exportin-5. miRNA is synthesized as a long precursor termed a primary miRNA (pri-miRNA). 21 Processing of pri-miRNA by Drosha RNAse III endonuclease in the nucleus liberates a 60-70 nucleotide stem-loop intermediate known as the miRNA precursor (pre-miRNA). PremiRNA is actively transported from the nucleus to the cytoplasm by an exportin-5-dependent process. It is then further processed by Dicer and RNA-induced silencing complex into 21-to 23-nucleotide mature miRNA. Yi et al. 22 showed that overexpressed shRNAs saturated the activity of endogenous exportin-5 and inhibited miRNA function. Overexpression of exportin-5 reversed this effect and significantly enhanced siRNA-mediated gene silencing. In contrast, exogenously introduced siRNA does not usually induce cell toxicity, 23 suggesting that these siRNAs entered the RNAi pathway at a later step, thus avoiding the saturation of exportin-5 or other early factors. These studies raise the safety concern with the approach of expressing stable and high-level shRNA to treat human diseases.
Expression of siRNAs against HIV-1 frequently led to the emergence of HIV escape variants. 13 , 15 Sequence analysis of these escape variants revealed that the siRNA target sites in the HIV-1 genome contained nucleotide changes. The rapid replication kinetics of HIV-1 and the error-prone nature of viral reverse-transcriptase most likely led to the selection of viral quasispecies with mutations in the siRNA target site, thereby eliminating the siRNA antiviral effect. These studies suggest that, similar to the present antiviral drug therapy paradigms, gene delivery vectors capable of expressing multiple siRNAs targeted to different regions of the HIV-1 genome need to be developed to reduce the probability of generating HIV-1 escape mutants. However, due to the potential toxicity induced by shRNA overexpression, expression of different anti-HIV shRNA genes from multiple pol III promoters may not be a viable option in the setting of human gene therapy trials. In contrast to pol III promoters, pol II promoters may represent a better choice for shRNA gene expression. Pol II promoters are generally less active than pol III promoters. Pol II promoters offer the advantage of tissue specificity that limits ubiquitous siRNA expression. In addition, inducible pol II promoters may allow the modulation of the siRNA expression level and ultimately reduce the side effect generated by constitutive siRNA expression. Zeng et al. 24 first demonstrated the feasibility of using a pol II promoter to drive designed miRNA expression that blocked the translation in human cells of an mRNA containing the target site. Stegmeier et al. 25 used a tetracycline-inducible promoter to modulate the expression of a designed miRNA and achieved tetracyclineresponsive knockdown of gene expression. These studies provide support for our approach of using pol II promoters to drive the expression of anti-HIV siRNAs.
In the current study, we took the strategy of replacing the original stem sequence in the stem-loop structure of the well-characterized miR-30a with anti-HIV siRNA sequences. We showed that when expressing these designed miRNA from a pol II promoter, inhibition of HIV-1 replication could be achieved. The efficacy was directly correlated with the level of siRNA expression as siRNA expressed from a pol III promoter was much more efficacious than that from a pol II promoter. We also demonstrated that a combination of pol II and pol III promoters to express two different siRNAs increased the efficacy against HIV-1 replication without comprising cell viability.
Results
Emergence of HIV-1-resistant mutants from siRNAexpressing T cells
To study siRNA-mediated inhibition of HIV replication, we constructed two shRNA genes against HIV-1 gag and a common exon shared by tat and rev messages, respectively. The shRNA gene was placed under the control of the H1 promoter and inserted into pHIV7/SFgreen fluorescent protein (GFP), a third-generation HIV vector containing the GFP gene controlled by the promoter of spleen focus-forming virus (SFFV).
26 H9 cells were transduced with these vectors (HIV7/H1-tr and HIV7/H1-gag, see Figures 2b and 4a) and challenged with infectious HIV-1 NL4-3 . Although siRNAexpressing cells efficiently inhibited HIV replication at a low challenge dose, 27 HIV-1 escape mutants were observed at a higher challenge dose irrespective of the siRNA expressed ( Figure 1a ). To explore the potential reason for the emergence of such resistant mutants, the HIV-1 RNA genome in the culture of HIV7/H1-gagtransduced cells was reverse transcriptase (RT-PCR) amplified, cloned and the region spanning the gag siRNA target site was sequenced. While no sequence variation for up to 300 bp could be detected in the regions flanking the siRNA target site, point mutation was observed within the target site in different clones ( Figure 1b ). Re-challenging HIV7/H1-gag-transduced cells with the harvested escape mutants demonstrated that these were 'true' escape mutants and they no longer responded to the siRNA silencing effect (data not shown). Thus, similar to drug therapy, the approach of expressing a single siRNA is likely to select out viral quasispecies with mutation in the siRNA target site. To reduce the probability of generating such escape mutants, vectors capable of expressing multiple siRNAs against different regions of the HIV-1 genome need to be developed.
Induction of cell toxicity by siRNA overexpression
The size of the cassette including the H1 promoter and the shRNA gene is approximately 300 bp. Insertion of multiple such units expressing siRNAs against different regions of the HIV-1 genome can be accommodated as a single HIV vector has the capacity for up to 7 to 8-kb foreign DNA insertion. However, insertion of multiple pol III transcription units in a single vector may lead to siRNA overexpression in the transduced cells and result in cell toxicity. To determine whether siRNA expression can generate side effect in our system, we first compared Inhibit HIV replication with designed miRNA H-L Lo et al the relative strength of two commonly used pol III promoters: the H1 and U6 promoters. The shRNA gene against the tat/rev transcript was placed under the control of these promoters and co-transfected with a luciferase (luc) reporter construct containing the target sites for the siRNA. In transiently transfected 293T cells, siRNA expressed from the U6 promoter was capable of reducing the luc activity 200-fold whereas siRNA from the H1 promoter could only reduce the luc expression 54-fold (Figure 2a ). This result suggests that the U6 promoter is more active than the H1 promoter in 293T cells. This is consistent with the recent study by An et al. 19 showing a similar effect of these two promoters in lymphocytes. To determine whether the level of siRNA affects cell viability, we inserted the U6-tr and H1-tr cassette into pHIV7/SF-GFP to generate HIV7/U6-tr and HIV7/H1-tr (Figure 2b ). Primary human peripheral blood mononuclear cells (PBMCs) were transduced with each vector and the fraction of GFP+ cells was monitored at different time after transduction. Cells transduced with HIV7/SF-GFP showed a slight increase in the fraction of GFP+ cells during a 4-week follow-up (Figure 2b ). HIV7/H1-tr transduced cells showed a o2-fold reduction in the GFP+ cell fraction. In contrast, the GFP+ fraction of HIV7/U6-tr-transduced cells was dramatically reduced and very little GFP+ cells could be detected beyond 2 weeks after transduction (Figure 2b ). To determine whether such reduction was due to gene-expression silencing or due to the loss of the transduced cells, the average vector copy number in each cell population was determined at 7 and 28 days after transduction by realtime PCR of the isolated genomic DNA. As shown in Figure 2b , the vector copy in HIV7/U6-tr transduced cell population was significantly reduced from 1.4 copies per cell to 0.1 copies per cell during the period of 3 weeks. The vector copy in HIV7/H1-tr transduced cells was reduced from 0.9 copies per cell to 0.4 copies per cell whereas the vector copy showed a slight increase in HIV7/SF-GFP transduced cells during the same period. The change in vector copy is consistent with the observed GFP+ cell fraction in each population. This result suggests that cell loss, possibly due to the competition of shRNA with endogenous miRNAs for processing or nuclear export, but not gene-expression silencing causes the dramatic reduction of the GFP+ fraction in HIV7/U6-tr transduced cells.
Development of pol II promoter-driven siRNA expression
Almost all miRNA are expressed from pol II promoters and some of the transcripts are polycistronic containing multiple miRNA sequences, suggesting a strategy to express multiple anti-HIV siRNAs from a single transcript. To evaluate the potential of using pol II promoter to express anti-HIV siRNA, we replaced the stem in the well-characterized pri-miR-30a with the stem of the siRNA against tat/rev to generate tr1 ( Figure 3a ). Due to potential processing by Drosha and Dicer, the resulting short double-stranded RNA is expected to have an A:U pair at the left end and a G:C pair at the right end. Based on the rule of strand bias for RNA-induced silencing complex incorporation, the strand complementary to siRNA will be preferentially incorporated into the RNAinduced silencing complex, thereby reducing the potential efficacy for the siRNA. 28 To overcome this problem, we shifted the target sequence by one nucleotide and generate tr2 (Figure 3a) . The resulting double-stranded RNA is predicted to have a G:C pair at the left end and an A:U pair at the right end and the siRNA strand is predicted to get incorporated preferentially into the RNA-induced silencing complex. The designed miRNA gene was placed under the control of the H1 promoter and transfected with the luc reporter construct into 293T cells and the luc activity was determined. As shown in Figure 3b , both tr1 and tr2 reduced the luc activity although tr2 was at least eightfold more efficient than tr1. This is consistent with the model that the strand incorporated into RNA-induced silencing complex is Inhibit HIV replication with designed miRNA H-L Lo et al mostly the one whose 5 0 -end is less tightly paired. 28 A negative control, pH1-hypoxanthine phosphoribosyltransferase (hprt), containing a shRNA gene specific for the mRNA of hypoxanthine phosphoribosyltransferase (hprt) was unable to downregulate the luc activity (Figure 3b ), demonstrating the specificity of this gene silencing effect. We also evaluated whether the designed miRNA was capable of inhibiting HIV-1 production in a transient co-transfection assay when the target existed in its natural context: in the HIV-1 genome. The harvested HIV-1 was used to infect Magi cells containing the b-gal gene controlled by the HIV-1 long terminal repeat. 29 As HIV-1 infection activates b-gal expression, the b-gal level reflects the relative titer of the input virus. As shown in Figure 3c , both pH1-tr1 and pH1-tr2 efficiently inhibited HIV-1 production from 293T cells. Again, tr2 functioned more efficiently than tr1 in this assay. A similar strategy was also used to evaluate two designed miRNA, gag1 and gag2, against the gag transcript (Figure 3d ). Gag1 has A:U pair at both ends of the double-stranded RNA Inhibit HIV replication with designed miRNA H-L Lo et al whereas gag2 has G:C pair at one end and A:U pair at the other. As shown in Figure 3e , gag2 was more efficient to inhibit luc expression than gag1 in transfected 293T cells.
To verify further the specificity of gene silencing, we cotransfected each siRNA expression plasmid with pC-gp and pCMV-rev, the expression plasmids for HIV-1 Gag/ Pol and Rev, respectively, into 293T cells and performed a western blot analysis to detect p24 production 40 h later. As shown in Figure 3f , the HIV-1-specific siRNA, either in the form of shRNA or designed miRNA, efficiently suppressed p24 production whereas the nonspecific hprt shRNA failed to affect the p24 level. This result clearly suggests that the siRNA-induced gene silencing effect has specificity and is not caused by miRNA-mediated global translational inhibition.
To determine whether a pol II promoter can be used to drive the expression of the designed miRNA gene, the tr2 gene was placed under the control of the promoter derived from Rous sarcoma virus (RSV) to generate pRSV-tr2 (Figure 3g ). We also inserted the GFP gene between the RSV promoter and the designed miRNA gene to generate pRSV-GFP-tr2 to evaluate whether an extended 5 0 -region in the transcript may facilitate more efficient processing of the designed miRNA by Drosha. A previous study by Stegmeier et al. 25 showed that extending the 5 0 -region of a designed miRNA led to an increased efficacy of the process siRNA. As shown in Figure 3g , both constructs were capable of reducing reporter luc expression in 293T cells and pRSV-GFP-tr2 functioned more efficiently than pRSV-tr2. Inhibition of HIV-1 production could also be demonstrated with either pRSV-tr2 or pRSV-GFP-tr2 (Figure 3h ). Together, these results clearly demonstrated that the siRNA gene silencing activity could be derived from a designed miRNA and the activity was as efficient as the shRNA in these transient assays described. The gene encoding the designed miRNA could be expressed from either a pol II or a pol III promoter and resulted in efficient silencing of HIV-1 production from 293T cells.
Effect of vector copy number and promoter on the inhibition of HIV-1 replication
To compare the efficacy of pol II and pol III promoterdriven siRNA expression, the tr2 gene was inserted downstream from the GFP gene in HIV7/SF-GFP to generate HIV7/SF-tr2 (Figure 4a ). H9 populations transduced with either HIV7/H1-tr or HIV7/SF-tr2 at different multiplicity of infection were established. The genomic DNA from each cell population was used for vector copy number determination with quantitative real-time PCR. The HIV-1 challenge assay shown in Figure 4b demonstrated that the HIV7/SF-tr2-derived cell population containing 1.870.2 integrated vector copies was incapable of inhibiting HIV-1 replication whereas a similar cell population with 10.470.6 integrated vector copies efficiently inhibited HIV-1 replication. In contrast, a HIV7/H1-tr-derived cell population with an average of 1.870.1 integrated vector copies efficiently inhibited HIV-1 replication in the same challenge assay. Similar results were obtained when the challenge dose was increased from 350 to 5000 infectious HIV-1 NL4-3 viral particles (Figure 4c ), although in this case escape mutants became detectable in all the cell populations. Nevertheless, the HIV7/H1-tr-derived cell population was still more efficient than other cell populations to suppress HIV-1 replication. The observed efficacy could be attributed to the overall level of siRNA expressed in the transduced cells as evidenced by the fact that a pol III promoter was generally more efficient in its activity than a pol II promoter and the deficiency of the SFFV promoter could be partially compensated by the introduction of multiple copies of the same vector into the cells.
To verify the expression of siRNA in vector-transduced cells, total RNA were isolated and the mature siRNA was detected with RT-PCR using a newly available small RNA quantitation system (see Materials and methods section). The gag siRNA could only be detected in HIV7/H1-gag-transduced cells but not in HIV7/SF-GFP-, or HIV7/SF-tr2-transduced cells ( Figure  4d, upper panel) . In contrast, the tr siRNA was only detected in HIV7/SF-tr2-, and HIV7/H1-tr-transduced cells (Figure 4d, lower panel) , confirming the generation of the tr siRNA from either the pol II or the pol III promoters. To determine whether the level of siRNA is related to the vector copy number, a semiquantitative RT-PCR analysis was carried out using RNA isolated from H9 cells containing different copies of the vector. As shown in Figure 4e , the level of siRNA expression was correlated with the average vector copy in each cell population. The gene silencing activity of gag1 and gag2. A luc reporter plasmid carrying two copies of the gag siRNA target site was co-transfected with the indicated plasmid into 293T cells and the luc activity was determined as described in (b). (f) Downregulation of Gag by the siRNA. 293T cells were co-transfected with 2 mg of pC-gp, pCMV-rev 37 and 5 mg of the indicated plasmid. The cell extract was prepared 40 h later and western blot was performed to detect HIV-1 Gag using a mouse anti-HIV-1 p24 monoclonal antibody. For loading controls, the membrane was reprobed with a rabbit antiactin antibody. (g) The gene silencing activity of tr2 expressed from a pol II promoter. The luc reporter plasmid was co-transfected with the indicated plasmid into 293T cells and the luc activity was determined and normalized to the activity in cells transfected with pRSV containing the RSV promoter only. (h) Suppression of HIV-1 production by tr2 expressed from the RSV promoter. pNL4-3 was co-transfected with the indicated plasmid into 293T cells and HIV-1 produced was analyzed as described in (c). The data in Figure 3 represents the average of at least three independent experiments with s.d. CMV, cytomegalovirus; HIV, human immunodeficiency virus; miRNA, microRNA; RSV, Rous sarcoma virus; siRNA, small interfering RNA.
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Increased anti-HIV efficacy with the expression of two siRNAs
Although siRNA expressed from the less potent SFFV promoter showed reduced efficacy, it also minimized the risk of inducing toxicity due to siRNA overexpression. We addressed whether a combination of two different siRNAs in the same vector, one expressed from the H1 promoter and the other from the SFFV promoter ( Figure  4a ), could have an additive effect on efficacy. HIV7/gagtr2 containing the gag shRNA gene controlled by the H1 promoter and the tr2 designed miRNA gene controlled by the SFFV promoter was used to establish a pooled H9 cell population (Figure 5a ). The vector copy number in this population was determined to be 1.7 on average, similar to the average vector copy in cells transduced with HIV7/H1-gag or HIV7/SF-tr2 alone. RT-PCR confirmed the expression of the mature siRNA in the established culture (Figure 4d, lane 6) . We compared these H9 cell populations for their ability to inhibit HIV-1 replication at different challenge doses. As shown in Figure 5a , with a challenge dose of 1000 infectious viral particles, H9 cells containing 1.8 copies of HIV7/SF-tr2 failed to inhibit HIV-1 replication whereas H9 cells containing 1.6 copies of HIV7/H1-gag was capable of inhibiting HIV-1 replication at least 10-fold more efficiently at day 10 after challenge. The efficacy of HIV7/gag-tr2 was improved approximately 2-to 3-fold relative to HIV7/H1-gag at day 10 after challenge although this difference was less obvious by day 15 Inhibit HIV replication with designed miRNA H-L Lo et al when escape mutants started to emerge in culture. In contrast, with a lower challenge dose of 350 infectious particles, both HIV7/H1-gag and HIV7/gag-tr2-derived H9 cell populations efficiently suppressed HIV replication during a period of 4 weeks in culture (data not shown). We also analyzed the efficacy of human PBMCs transduced with these vectors. As shown in Figure 5b , only background levels of HIV-1 replication could be detected in the PBMC culture stably transduced with HIV7/gag-tr2 whereas low levels of HIV-1 replication were consistently detected in the culture transduced with HIV7/H1-gag. Like H9 cells, the PBMC culture transduced with either HIV7/SF-GFP or HIV7/SF-tr2 was incapable of inhibiting HIV-1 replication. As the average integrated vector copy in all these PBMC cultures was relatively similar, we concluded that a combination of two siRNAs in a single vector with different expression levels could have an increased efficacy than either siRNA alone. The viability of the cells transduced with HIV7/ gag-tr2 was similar to that of the cells transduced with HIV7/H1-gag (data not shown), suggesting that expression of an extra copy of the siRNA gene from the relatively weak SFFV promoter did not worsen the cell toxicity problem induced by siRNA overexpression.
Discussion
Introduction of siRNAs into cells has proven to be a powerful tool to silence gene expression. As the effect is potent and sequence specific, it may represent an effective approach to attenuate HIV-1 replication. Several studies have shown that HIV-1 replication could indeed be inhibited efficiently by siRNAs against various regions in the HIV-1 genome. 5, [12] [13] [14] [15] [16] [17] However, some of these studies also demonstrated the emergence of HIV escape variants with mutation in the siRNA target site. Our current study using a siRNA against the gag transcript again confirms these previous observations, suggesting that like drug therapy, concurrent expression of multiple siRNA against different regions of the HIV genome may be required to effectively suppress the emergence of these escape variants. A single HIV vector is capable of accommodating multiple pol III transcription units with a unit size of 200-300 bp. However, several recent studies demonstrated the risk of inducing cell toxicity due to siRNA overexpression. 19, 20, 22 This is consistent with our observation of dramatically reduced GFP+ cells in PBMCs transduced with HIV7/U6-tr containing the shRNA gene controlled by the strong U6 promoter. While cells transduced with HIV7/H1-tr are as viable as cells transduced with the control vector (data not shown), there is a risk of inducing cell toxicity if multiple transcription units containing the shRNA controlled by the H1 promoter were expressed concurrently in the transduced cells. Ter Brake et al. 30 have constructed a HIV vector with two anti-HIV shRNA genes controlled by separate H1 promoters. While no cell toxicity was reported in the supT1 cells they established, primary human PBMCs we used might be more sensitive to the shRNA level. Moreover, escape variants emerged from cells expressing two siRNAs as reported by Ter Brake et al., 30 suggesting that more than two siRNAs might have to be expressed to effectively suppress HIV-1 replication. Since efficient inhibition of HIV replication may require long-term siRNA expression in the target cell, the potential risk of overexpressing siRNA from multiple H1 promoters precludes the use of such a strategy to treat HIV infection.
As it is rather difficult to modulate the activity of pol III promoters, we opted to use pol II promoters for siRNA expression. Unlike the ubiquitous activity of pol III promoters, many tissue-specific pol II promoters are well characterized and will allow restricted expression of the siRNA in specific cell types. The presence of inducible promoters may ultimately allow the modulation of siRNA expression by exogenously added inducers. As a pol II promoter generally is not as strong as a pol III promoter, it reduces the potential of inducing cell toxicity. Most importantly, the presence of polycistronic messages containing multiple miRNA sequences suggests that a single pol II promoter may direct the expression of multiple siRNA genes from a HIV vector. We replaced the stem structure in miR-30a with the double-stranded siRNA against HIV-1 and placed the designed miRNA gene under the control of either pol III or pol II promoters. While all these constructs exhibited strong anti-HIV activity in a transient assay, stable siRNA expression from a pol II promoter clearly had reduced efficacy than that from a pol III promoter when introduced via a HIV vector. The weak promoter activity of the SFFV promoter that we used could account for the reduced efficacy. However, our previous studies have shown that the activity of this promoter was at least 2-to 3-fold stronger than that of the immediate-early promoter of cytomegalovirus (CMV) in various hematopoietic lineages including human T lymphocytes. 26 Mean fluorescence intensity of GFP in transduced cells also Inhibit HIV replication with designed miRNA H-L Lo et al suggested that this promoter was reasonably efficient in T cells (data not shown). Besides the fact that the activity of a pol III promoter is much stronger than that of a pol II promoter, additional steps required to process the pol IIderived designed miRNA into shRNA by Drosha may also account for the reduced efficacy. The relationship between the siRNA expression level and the efficacy gained further support by the demonstration that multiple copies of the pol II promoter-containing vector were capable of efficiently inhibiting HIV replication ( Figure  4b) . However, such a strategy is unlikely to be adopted in a gene therapy trial at present due to the increased risk of insertional mutagenesis. 31, 32 To use a relatively weak pol III promoter such as the H1 promoter in combination with a pol II promoter to express two or more siRNA genes as demonstrated in our study may represent a suitable strategy to suppress HIV replication and minimize the induction of cell toxicity. Our result in primary PBMCs clearly demonstrated an additive advantage of expressing two siRNAs with such a strategy. Inserting more miRNA-siRNA hybrid genes that target different regions in the HIV-1 genome downstream from the pol II promoter should further enhance the anti-HIV activity of such vectors. Selecting stronger T-cell-or macrophagespecific pol II promoters to drive multiple siRNA expression should also increase the efficacy and reduce the potential of generating off-target effect in unintended cell types, although restricted siRNA expression can still induce side effect in T cells or macrophages. Using tissuespecific inducible promoter such as the interleukin-2 promoter may impact to a lesser extent on normal miRNA processing. Interleukin-2 transcription is induced upon T-cell activation. 33 In addition, interleukin-2 promoter in activated T cells can be superinduced by HIV Tat. 34 Promoters such as this therefore fulfills the promises of regulated siRNA expression to minimize its side effect but achieve maximum efficacy. On the basis of our studies, systematic screening of the HIV-1 genome to find the most efficient siRNA target sites should also facilitate more efficient suppression of HIV replication as lower levels of an efficient siRNA may be sufficient to generate sufficient efficacy against HIV-1.
In summary, our study exhibits the effect of vector copy number and the promoter used. It demonstrates that the siRNA level is ultimately linked to its efficacy. As siRNA overexpression induces off-target effect and cell toxicity, the intracellular level of siRNA needs to be balanced to confer efficacy but not induce side effect. Proper design of the designed miRNA to maximize Drosha-mediated processing, screening of the HIV-1 target for more efficient siRNAs, the selection of efficient promoters for cell-specific or inducible siRNA expression and the use of optimal siRNA combinations will ultimately determine the success of applying siRNA-mediated gene therapy approach to treat HIV infection. Our current study represents an initial step toward this goal.
Materials and methods
Cell culture
293T, HT1080 and Magi cells were maintained in high glucose (4.5 g l À1 ) Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM Lglutamine and 100 mg ml À1 gentamycin. H9 cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 100 mg ml À1 gentamycin. PBMCs from healthy donors were isolated by Ficoll-Hypaque (Amersham Biosciences, Uppsala, Sweden). The cells were co-stimulated with anti-CD3 and anti-CD28 antibodies immobilized onto paramagnetic beads (Dynal Biotech LLC, Brown Deer, WI, USA). To stimulate cell proliferation, 10 6 PBMCs were seeded onto a plate coated with 50 g ml À1 Retronectin (Biowhittaker, Walkersville, MD, USA). Dynabeads coated with the antibodies against CD3 and CD28 were added at a ratio of 3 beads per cell. The cells were stimulated for 18 h in RPMI-1640 supplemented with 10% fetal bovine serum and 2 mM L-glutamine.
Plasmids
Construction of pH1, pHIV7/SF-GFP, HIV7/H1-tr and HIV7/H1-gag has been described previously. 26, 27 The U6 promoter was amplified from the human genomic DNA as described 35 with primers 5 0 -GGGAATTCCCCCAGTG GAAAGACGCGCAG-3 0 and 5 0 -CGGAAGCTTGAA GACCACGGTGTTTCCACAA-3 0 , in which a BbsI site was introduced at the 3 0 -end to allow shRNA gene insertion at the +1 position of the U6 transcript. The amplified promoter was cloned into pBluescript SK (À) to generate pU6. To construct pU6-tr, two oligonucleotides with the sequences 5 0 -ACCGCAGAACAGTCA GACTCATCAATTCAAGAGATTGATGAGTCTGACTGT TCTGCTTTTTGGAAAGGATCC-3 0 and 5 0 -TCGAGGAT CCTTTGGAAAAAGCAGAACAGTCAGACTCATCAATC TCTTGAATTGATGAGTCTGACTGTTCTG-3 0 were synthesized, annealed and cloned into BbsI and XhoI-digested pU6. To generate pSK-miR-30a, a 250-bp DNA fragment containing the miR-30a sequence was amplified from pSM2C (Open Biosystems, Huntsville, AL, USA) and cloned into the EcoRI site in pBluescript SK (À). To generate pSK-miR30-tr2, an oligonucleotide with the sequence 5 0 -TGCTGTTGACAGTGAGCGCAGAACAGT CAGACTCATCAATAGTGAAGCCACAGATGTATTGA TGAGTCTGACTGTTCTGTGCCTACTGCCTCGGA-3 0 was synthesized and amplified by PCR with the following primers: 5 0 -CAGAAGGCTCGAGAAGGTA TATTGCTGTTGACAGTGAGCG-3 0 and 5 0 -CTAAAG TAGCCCCTTGAATTCCGAGGCAGTAGGCA-3 0 . The PCR-amplified fragment was digested with XhoI and EcoRI and cloned into pSK-miR-30a to generate pSKmiR30-tr2. The H1, U6 and RSV promoter were cloned into the unique Not1 site in pSK-miR30-tr2 to generate pH1-tr2, pU6-tr2 and pRSV-tr2, respectively. The pSKmiR30-tr1, gag1 and gag2 were also similarly constructed. The tr2 or gag2 gene was then subcloned downstream from the GFP gene in pHIV7/SF-GFP to generate pHIV7/SF-tr2 and HIV7/SF-gag2.
Transfection with shRNA expression plasmids
Fifteen micrograms of each siRNA expression plasmid was co-transfected with 5 mg of the luciferase (luc) reporter plasmid or 2 mg of pNL4-3 into 293T cells using the calcium phosphate co-precipitation method. 36 Cell lysates were collected 48 h after transfection for the luc assay 
HIV vector production and cell transduction
To produce infectious HIV vectors, 293T cells were plated at a density of 2 Â 10 6 per 100-mm culture dish 24 h prior to transfection. The cells were co-transfected with 12 mg of pCgp, 4 mg of pCMV-rev, 2 mg of pCMV-G and 10 mg of the vector plasmid by calcium phosphate co-precipitation as described previously. 36 The culture medium was replaced with fresh medium after 6 h. The culture supernatant was collected 40 h after transfection and stored at À801C. To determine the vector titer, 1 Â 10 5 HT1080 cells were plated in six-well plates 24 h prior to transduction. The cells were transduced with various dilutions of the harvested culture supernatant for 6 h in the presence of 4 mg ml À1 polybrene. The culture medium was replaced with fresh medium and the vector titer was determined by fluorescence-activated cell sorting analysis for GFP-positive cells. Transduced H9 cells were isolated by cell sorting of GFP+ cells.
HIV-1 challenge
Approximately 5 Â 10 5 H9 cells expressing the siRNA were infected with HIV-1 NL4-3 at an indicated dose. The titer of HIV-1 was determined by infecting Magi cells and scored for b-gal-positive cells. At the indicated time point, HIV-1 replication was measured by the p24 enzyme-linked immunosorbent assay kit (Beckman Coulter, Fullerton, CA, USA) of the harvested culture supernatant. PBMCs were transduced for 16 h at a multiplicity of infection of 5. The transduced culture was maintained in RPMI medium supplemented with 10% fetal bovine serum and 50 U ml À1 interleukin-2 (R&D, Minneapolis, MN, USA). The transduction efficiency was measured by fluorescence-activated cell sorting after day 5. For HIV-1 challenge, approximately 5 Â 10 5 transduced PBMCs stimulated by CD3/CD28 Dynal beads were seeded onto 24-well plates. The cells were infected with infectious HIV-1 NL4-3 particles at the indicated dose. After 24 h, the cells were washed two times, and supernatant collected. The cells were passaged, and supernatant was collected two times weekly for p24 measurement.
Quantitative real-time PCR
To quantify the vector copy number, total genomic DNA from the transduced cells was isolated by GenElute Mammalian Genomic DNA miniprep kit (Sigma, St Louis, MO, USA). Quantitative real-time PCR were carried out as triplicate for each sample with SYBR Green PCR Master Mix (Applied Biosystems). Primers used for Q-RT PCR were designed by Primer Express Software (Applied Biosystems) to specifically detect the RRE-flap region in the vector. The sequences of the PCR primers are: 5 0 -CAAGAATCCTGGCTGTGGAAAG-3 0 and 5 0 -CTGCCATTTGTAGATCCAAGGC-3 0 . The templates for the standard curve are determined using 0.13-1330 pg HIV7/SF-GFP vector plasmid DNA mixed with 100 ng untransduced cell genomic DNA to represent 1-10 000 copies of the transgene. The transgene copy number in each cell population was calculated based on the threshold cycle (C t ) of the standard curve with R 2 ¼ 0.9948. For detecting siRNA, total RNA from transduced H9 cells was isolated by the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) and quantified by RT-PCR using the QuantiMir RT Kit Small RNA Quantitation System (System Biosciences, Mountain View, CA, USA). The forward primers have the following sequences: for the gag siRNA, 5
0 -AGCCTGTCTCTCAG TACAA-3 0 and for the tr siRNA, 5 0 -TTGATGAGTCT GACTGTTCT-3 0 . The band density of PCR was analyzed by the software of Quantity One (Bio-Rad, Hercules, CA, USA).
Western blot
Seventy-five micrograms of protein from transfected 293T cell lysates was fractionated in 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and proteins were transferred onto nitrocellulose membranes (BioRad). Mouse anti-HIV-1 p24 Gag monoclonal antibody was obtained from the NIH AIDS Reference & Reagent Program. Secondary peroxidase-conjugated goat antimouse antibody (Jackson ImmunoResearch, PA, USA) and enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech, Buckinghamshire, UK) were used to detect the signal. For loading controls, membranes were stripped in 50 1C using stripping buffer (2% sodium dodecyl sulfate, 100 mM b-mercaptoethanol and 50 mM Tris, pH 6.8) for 15 min and re-probed using rabbit antiactin antibody (Sigma).
